



April 1, 2014

Peregrine Pharmaceuticals Announces Three Abstracts Accepted for Presentation at AACR 2014 Annual Meeting

TUSTIN, CA -- (Marketwired) -- 04/01/14 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), a biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today announced the acceptance of three preclinical abstracts scheduled for poster presentations at the 105th Annual Meeting of the American Association for Cancer Research (AACR), to be held April 5-9, 2014 in San Diego, California. Data to be presented include studies investigating the therapeutic potential of Peregrine's phosphatidylserine (PS)-targeting antibodies when administered in combination treatment regimens with irradiation as well as with approved and developmental cancer immunotherapies.

Abstract Details:

[Abstract Number: 639](#)

Presentation Title: Antibody-mediated blockade of phosphatidylserine combined with radiation improves survival and tumor eradication in a rat model of non-small cell lung cancer

Presentation Time: Sunday, April 6, 2014, 1:00 PM - 5:00 PM

Location: Hall A-E, Poster Section 27

Poster Board Number: 14

Author Block: Olivier Belzile, Zhang Zhang, Xianming Huang, Debabrata Saha, Rolf A. Brekken. University of Texas Southwestern Medical Center, Dallas, Texas

[Late-Breaking Abstract Number: LB-262](#)

Presentation Title: Phosphatidylserine-targeting antibody synergizes with anti-PD-1 antibody to inhibit tumor growth in K1735 mouse melanoma model

Presentation Time: Tuesday, April 8, 2014, 1:00 PM - 5:00 PM

Location: Hall A-E, Poster Section 41

Author Block: Xianming Huang, Dan Ye, Rolf Brekken, Yi Yin. UT Southwestern Medical Center, Dallas, Texas

[Abstract Number 4978](#)

Presentation Title: Targeting of phosphatidylserine by monoclonal antibodies enhances activity of immune checkpoint inhibitors in tumors

Presentation Time: Wednesday, April 9, 2014, 8:00 AM -12:00 PM

Location: Hall A-E, Poster Section 7

Poster Board: 2

Author Block: Jian Gong, Van Nguyen, Shen Yin, Rich Archer, Jeff Hutchins, Bruce Freimark. Peregrine Pharmaceuticals, Inc., Tustin, California

About Peregrine Pharmaceuticals, Inc.

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a pipeline of novel drug candidates in clinical trials for the treatment and diagnosis of cancer. The company is developing multiple clinical programs in cancer with its lead immunotherapy candidate bavituximab while seeking a partner to further advance its novel brain cancer agent Cotara®. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and third-party customers. Additional information about Peregrine can be found at www.peregrineinc.com.

Contact:

Christopher Keenan or Jay Carlson

Peregrine Pharmaceuticals

(800) 987-8256

info@peregrineinc.com

Source: Peregrine Pharmaceuticals

News Provided by Acquire Media